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A 43-year-old Caucasian female was diagnosed with Philadelphia-chromosome positive chronic myelogenous leukemia (CML). She received hydroxyurea for 10 months, followed by an allogeneic 6/6 HLA-matched peripheral stem cell transplant from her brother after being conditioned with busulphan and cyclophosphamide. A total of 12.8 Â 10 6 CD34-positive stem cells/kg body weight were infused without complications. Single-agent tacrolimus for graft-versus-host disease (GVHD) prophylaxis was initiated. The post-PSCT course was complicated by GVHD involving skin, orbital cellulitis, neutropenic fever and thyroiditis. These complications resolved with antibiotics and prednisone. Subsequently the prednisone was weaned off over a 6-month period. Tacrolimus levels were maintained at 5-10 ng/ml and eventually discontinued at 27 months post transplantation. Although on tacrolimus her serum AST and ALT levels increased to 723 and 965 IU/l, respectively. Her serum bilirubin level was 0.6 mg/ dl and alkaline phosphatase was 96 IU/l. Other laboratory studies showed normal complete blood counts, creatinine, blood urea nitrogen, iron saturation, ferritin, ceruloplasmin, a 1antitrypsin and a-fetoprotein. Anti-nuclear antibody was positive with a nucleolar, homogeneous pattern (1:160). Other autoimmune markers were negative for anti-liver-kidney microsomal, anti-mitochondrial and antismooth muscle antibodies. She had negative serologies for hepatitis A, B, C, Epstein-Barr, cytomegalovirus and herpes zoster viruses. An abdominal sonogram was normal in echotexture and size. On physical examination she was moderately obese (body mass index 42 kg/m 2 ) with Cushingoid facies and without stigmata of chronic liver disease or portal hypertension. Liver biopsy (Figure 1 ) was as shown. There were no biliary changes, steatosis, evidence of recurrent CML and special stains for micro-organisms were negative. The histological changes were characteristic of those typically described in autoimmune hepatitis except for granuloma. The modified hepatitis activity index score and fibrosis stage were 8/18 and 3/6 respectively. 2 In situ hybridization was performed on the liver biopsy for the Y chromosome ( Figure 2 ). Her baseline diagnostic score according to the modified criteria of the International Autoimmune Hepatitis Group was 412 and that placed her in the category of definite autoimmune hepatitis.
1 She was begun on prednisone 20 and imuran 50 mg/day, which resulted in rapid normalization of the serum transaminase levels. She has remained stable during a subsequent followup period of 28 months.
This report documents a case of liver dysfunction following allogeneic PSCT, which was indistinguishable from 'definite' autoimmune hepatitis. 1 Occasional examples of de novo autoimmune-like hepatitis have been reported following liver, bone marrow or stem cell transplantation. [3] [4] [5] [6] [7] [8] Other etiologies including viral hepatitis, non-alcoholic steatohepatitis and metabolic liver disease were excluded. The diagnosis was distinguished from chronic GVHD as liver histopathology did not reveal any changes consistent with GVHD (Table 2) . 7 In the present case, as in the other reported cases, autoimmune hepatitis developed de novo, as there was no previous history of autoimmune liver disease. One intriguing feature of these cases is that the target liver cells and immune-reactive cells (lymphocytes) are apparently of different origins. The donor origin of immune reactive cells was clearly established in our female patient by in situ hybridization, labeling of the Y chromosome. Median time of onset of liver dysfunction in published cases was 8-12 months post BM/PSC transplantation, as in our case.
Although several factors have been recognized as influencing the development of autoimmune hepatitis, its pathogenesis remains far from clear. The pathogenesis is likely to be even more complex for alloimmune hepatitis. Immunosuppression with tacrolimus or cyclosporine has been shown to induce an autoimmune syndrome in rodents. [9] [10] [11] [12] It is unclear whether alloimmune hepatitis represents a true autoimmune-based attack against a shared epitope or is a variant form of alloantigen-based immune reaction. The coexistence of autoantibodies suggests that at least some element of autoreactivity is present in these patients. Breakdown of tolerance may require interference at several points along normally redundant control mechanisms. In this case, total body irradiation is thought to injure or destroy peripheral autoregulatory T cells and the use of cyclosporine after auto-transplant likely interferes with the elimination of self-reactive clones in the thymus. We speculate that a multi-step sequence of events may also underlie the state of anti-liver reactivity that resembles autoimmune hepatitis and occurs in a minority of hemopoietic cell or liver transplant patients. Further studies are needed to explore this point.
In summary, liver disease indistinguishable from autoimmune hepatitis may occur in the setting of bone marrow or PSCT. Recognition of this condition is important, because therapy typically used for autoimmune hepatitis is effective, and is likely associated with long-term clinical and pathological remission of disease. Many cells show the presence of a Y chromosome (green) in addition to an X chromosome (red) in this high powered view of part of a portal inflammatory cell infiltrate. The inflammatory infiltrate was determined to be of donor origin on this basis, and the parenchymal cells had an XX genotype as expected (propidium blue nuclear counterstain, Â 1000). 
